Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Shiri Davidi"'
Autor:
Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Publikováno v:
Cancers, Vol 15, Iss 4, p 1182 (2023)
The authors wish to make minor corrections to Figure 1 and Figure 2 of the following paper [...]
Externí odkaz:
https://doaj.org/article/59c4c5f11fdd4f7cafedcde1c5a12389
Autor:
Roni Blatt, Shiri Davidi, Mijal Munster, Anna Shteingauz, Shay Cahal, Adel Zeidan, Tal Marciano, Zeev Bomzon, Adi Haber, Moshe Giladi, Uri Weinberg, Adrian Kinzel, Yoram Palti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional, anti-mitotic treatment modality that targets rapidly dividing cancerous cells, utilizing low intensity, alternating electric fields at cancer-cell-type specific freq
Externí odkaz:
https://doaj.org/article/01d62b8fe64b4ea2ba3b073c3fa8e672
Autor:
Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Publikováno v:
Cancers, Vol 14, Iss 12, p 2959 (2022)
Hepatocellular carcinoma (HCC), a highly aggressive liver cancer, is a leading cause of cancer-related death. Tumor Treating Fields (TTFields) are electric fields that exert antimitotic effects on cancerous cells. The aims of the current research wer
Externí odkaz:
https://doaj.org/article/6a1ce5abde934875a09e3762212d6811
Autor:
Michal Munster, Ella Fremder, Valeria Miller, Neta Ben-Tsedek, Shiri Davidi, Stefan J Scherer, Yuval Shaked
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e95983 (2014)
Tumor derived microparticles (TMPs) have recently been shown to contribute to tumor re-growth partially by inducing the mobilization and tumor homing of specific bone marrow derived pro-angiogenic cells (BMDCs). Since antiangiogenic drugs block proan
Externí odkaz:
https://doaj.org/article/9aa513b95afd4f50832587cc0151743d
Autor:
Tali Voloshin, Mijal Munster, Yuval Shmueli, Uri Weinberg, Adi Haber, Anna Shteingauz, Helena Mumblat, Shiri Davidi, Shiri Danilov, Moshe Giladi, Einav Zeevi, Yoram Palti, Antonia Martinez-Conde, Adrian Kinzel, Catherine Tempel-Brami, Yaara Porat, Eyal Dor-On, Ori Braten, Carolina Lajterer, Rosa S. Schneiderman, Roni Blatt
Publikováno v:
Lung Cancer. 160:99-110
Objectives Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields with antimitotic effects on cancerous cells. TTFields concomitant with pemetrexed and a platinum agent are approved in the US and EU as
Autor:
Naama Flint-Brodsly, Einav Zeevi, Kerem Wainer-Katsir, Hila Fishman, Antonia Martinez-Conde, Eyal Dor-On, Mijal Munster, Yaara Porat, Tali Voloshin, Shiri Davidi, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Publikováno v:
Cancer Research. 83:2723-2723
Background: Gastric cancer, one of the most common types of cancers, is mainly treated with the FOLFOX chemotherapy regimen (oxaliplatin, fluorouracil [5-FU], and leucovorin); yet long-term survival remains poor. Tumor Treating Fields (TTFields) are
Autor:
Shay Cahal, Yaara Porat, Moshe Giladi, Eilon D. Kirson, A. Shteingauz, Adrian Kinzel, Aviran Itzhaki, Einav Zeevi, Uri Weinberg, Tali Voloshin, Yoram Palti, Catherine Tempel Brami, Mijal Munster, Noa Kaynan, Shiri Davidi, Rosa S. Schneiderman, Roni Blat
Publikováno v:
Cancer Immunology, Immunotherapy
Tumor-treating fields (TTFields) are alternating electric fields in a specific frequency range (100–300 kHz) delivered to the human body through transducer arrays. In this study, we evaluated whether TTFields-mediated cell death can elicit antitumo
Autor:
Adi Haber, Roni Blatt, Anna Shteingauz, Zeev Bomzon, Shiri Davidi, Shay Cahal, Adrian Kinzel, Uri Weinberg, Adel Zeidan, Moshe Giladi, Mijal Munster, Yoram Palti, Tal Marciano
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundTumor Treating Fields (TTFields) therapy is a non-invasive, loco-regional, anti-mitotic treatment modality that targets rapidly dividing cancerous cells, utilizing low intensity, alternating electric fields at cancer-cell-type specific freq
Autor:
Tali Voloshin, A. Shteingauz, Mijal Munster, A. Haber, Uri Weinberg, Karnit Gotlib, S. Jacobovitch, Yoram Palti, Shiri Davidi, Adrian Kinzel, E. Dor-On, Einav Zeevi, Rosa S. Schneiderman, C. Tempel Brami, Moshe Giladi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e47-e48
Purpose/Objective(s) Hepatocellular carcinoma (HCC) is a highly malignant liver cancer and is one of the leading causes of cancer-related mortality worldwide. Sorafenib, a multikinase inhibitor, is the main first-line treatment for advanced HCC, yet
Autor:
A. Martinez-Conde, A. Haber, S. Danilov, Uri Weinberg, C. Lajterer, C. Tempel-Brami, Y. Shmueli, Yaara Porat, Rosa S. Schneiderman, O. Braten, Yoram Palti, A. Shteingauz, R. Blatt, Shiri Davidi, Moshe Giladi, H. Mumblat, E. Dor-On, Einav Zeevi, Tali Voloshin, Adrian Kinzel, Mijal Munster
Publikováno v:
Journal of Thoracic Oncology. 16:S956-S957